Your browser doesn't support javascript.
loading
Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
Spreafico, A; Oza, A M; Clarke, B A; Mackay, H J; Shaw, P; Butler, M; Dhani, N C; Lheureux, S; Wilson, M K; Welch, S; Zhang, T; Yu, C; Stockley, T; Siu, L L; Kamel-Reid, S; Bedard, P L.
Affiliation
  • Spreafico A; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Oza AM; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Clarke BA; Department of Pathology and Laboratory Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Mackay HJ; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Shaw P; Department of Pathology and Laboratory Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Butler M; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Dhani NC; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Lheureux S; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Wilson MK; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Welch S; Division of Medical Oncology, Department of Oncology, London Health Sciences Centre, University of Western Ontario, London, ON, Canada.
  • Zhang T; Department of Pathology and Laboratory Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Yu C; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Stockley T; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Siu LL; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Kamel-Reid S; Department of Pathology and Laboratory Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Bedard PL; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. Electronic address: philippe.bedard@uhn.ca.
Gynecol Oncol ; 144(2): 250-255, 2017 Feb.
Article in En | MEDLINE | ID: mdl-28062115
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Neoplasms, Glandular and Epithelial Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2017 Type: Article Affiliation country: Canada
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Neoplasms, Glandular and Epithelial Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2017 Type: Article Affiliation country: Canada